Citations

Clear

2429 citation(s) found for "Shah, N".

Flexibility in Device Sizing with a Next-Generation LAA Occluder in the VERITAS Study
Makkar, Akash , Nair, Devi G , Agarwal, Himanshu , Abuissa, Hussam, Awad, Khaled , Backer, Ole De , Lakkireddy, Dhanunjaya, Ellis, Christopher R. , Shah, Dipak, Alkhouli, Mohamad, Nielsen‐Kudsk, Jens Erik , Weiler, Courtney , Freixa, Xavier

Mayo Clinic

Europace | November 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/europace/euag323 | PMID 43036870 Get It

Clinician Counseling and Patient Storage and Disposal Practices for Opioids Prescribed for Acute Pain: A Multicenter Prospective Cohort Study
Taherifard, Erfan , Ahadpour, Mitra , Chang, Nancy, Allen, Summer V. , Elie, Marie‐Carmelle , Fillmore, W. Jonathan , Gilbert, Gregg H. , Heckmann, Rebekah, Koussis, Patricia, Lee, Christine, Lipkind, Heather S. , Mallama, Celeste A. , Meyer, Tamra E. , Nuckols, Teryl K. , Ritchie, Jessica , Pacanowski, Michael , Page, David B. , Soukup, Mat, Tamang, Stephen, Torbati, Sam , Wallace, Doug, Walter, Lauren A. , Zhao, Yueqin, Shah, Nilay D. , Ross, Joseph S. , Jeffery, Molly Moore

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.11.04.26367278 Get It

ABSTRACT BACKGROUND Opioids prescribed for acute pain frequently remain unused, creating opportunities for unintended use, accidental ingestion, or diversion. Little is known about counseling patients receive from prescribers or pharmacists on storage and disposal of opioids. OBJECTIVE To characterize clinician counseling on opioid disposal and patient-reported storage, use, and disposal practices among opioid-naïve patients prescribed opioids for acute pain. DESIGN Multicenter prospective cohort study with participant recruitment between September 2020 and March 2023. PARTICIPANTS Opioid-naïve patients prescribed opioids for acute pain in emergency departments, primary care or urgent care clinics, inpatient settings, and dental practices. MAIN MEASURES Patient-reported receipt of counseling on the importance of opioid disposal and appropriate disposal methods; opioid storage practices; use and disposition of prescribed opioids; disposal methods; and reasons for keeping or disposing of leftover opioids. KEY RESULTS Among 1708 participants, the median age was 38 years (IQR, 28-52); most were recruited from emergency departments (n=915; 53.6%) and primary care or urgent care clinics (n=307; 18.0%). Among 1233 participants who answered the question on counseling about the importance of opioid disposal, 811 (65.8%) reported receiving no counseling. Among 1220 participants who answered the question on counseling about appropriate disposal methods, 832 (68.2%) reported receiving no counseling. Among 812 participants who answered the question about storing opioids in a locked location, 610 (75.1%) reported never doing so. Among 929 participants providing information on opioid leftovers and disposition, 618 (66.5%) did not use all prescribed opioids. Among these 618 participants, 258 (42.8%) kept leftover opioids and 345 (57.2%) disposed of them. Among 256 participants who reported reasons for keeping leftover opioids, 159 (62.1%) wanted medication available for the same condition, 70 (27.3%) wanted medication available for a different condition, and 36 (14.1%) did not know how to properly dispose of the medication. CONCLUSIONS Among opioid-naïve patients prescribed opioids for acute pain, counseling about opioid disposal was uncommon, secure storage was infrequent, and leftover opioids were frequent, with many patients keeping leftover opioids for possible future use. These findings suggest opportunities to improve counseling on opioid storage and disposal and encourage safe disposal of unused opioids after acute pain treatment.
Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review
Patel, Shivam , Gandhi, Akash , Pabani, Arman , Shah, Richa , Shah, Pal , Martinez, Matthew W , Bavishi, Aakash

Mayo Clinic

Journal of the American Heart Association | October 23, 2026 | Volume: 15 | Issue: 21 | Pages: No page available

10.1161/jaha.126.051256 | PMID 42924841 Get It

Background Nonobstructive hypertrophic cardiomyopathy (HCM) affects approximately one‐third of all patients with HCM and carries substantial morbidity, yet no approved disease‐modifying therapies exist. We conducted a systematic review of prospective interventional studies evaluating pharmacologic therapies in adults with nonobstructive HCM. Methods A systematic search of PubMed, Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov was performed through September 2025. Eligible studies included randomized and nonrandomized prospective interventional trials. A narrative synthesis was performed by pharmacologic class and outcome domain. Results Twenty‐nine clinical trials evaluating 9 pharmacologic classes were identified: cardiac myosin inhibitors, cardiac sarcomere modulators, metabolic modulators, angiotensin II receptor blockers, angiotensin receptor‐neprilysin inhibitors, mineralocorticoid receptor antagonists, SGLT2 (sodium‐glucose cotransporter 2) inhibitors, beta blockers, and calcium channel blockers. Cardiac myosin inhibitors demonstrated reductions in left ventricular hypertrophy, improvements in diastolic function, and marked reductions in cardiac biomarkers, although improvements in exercise capacity and symptoms were variable. SGLT2 inhibition showed concordant improvements in diastolic function, atrial remodeling, biomarkers, and functional status in patients with symptomatic nonobstructive HCM and comorbid type 2 diabetes. Angiotensin receptor blockade showed signals of structural remodeling with valsartan and candesartan without consistent functional benefit. Mineralocorticoid receptor antagonism and angiotensin receptor‐neprilysin inhibition demonstrated largely neutral effects. Among metabolic modulators, ninerafaxstat improved ventilatory efficiency and quality of life in patients with greater baseline symptom burden. Conclusions Pharmacologic responsiveness in nonobstructive HCM is variable and appears to be mechanism‐ and disease stage‐dependent. Ongoing trials evaluating cardiac myosin inhibitors, SGLT inhibitors, and novel therapeutic agents including ninerafaxstat and EDG‐7500 will be critical in further defining the therapeutic landscape.
Life-Course Blood Pressure Trajectories and Focal Myocardial Fibrosis in Older Age in MyoFit46
Topriceanu, Constantin-Cristian , Shiwani, Hunain , Martin, Emma , Falconer, Debbie , Bennett, Jonathan B. , Stanley, Matthew A , Gonzalez-Martin, Pablo , Tamang, Mansoon , Wong, Andrew , Pierce, Iain , Davies, Rhodri H , Lambiase, Pier D , Chaturvedi, Nishi , Kellman, Peter , Hardy, Rebecca , Moon, James C , Hughes, Alun D , Captur, Gabriella

Mayo Clinic

Hypertension | October 19, 2026 | Volume: 83 | Issue: 12 | Pages: No page available

10.1161/hypertensionaha.126.26702 | PMID 42895024 Get It

BACKGROUND: The impact of life-course blood pressure (BP) trajectories on later-life focal left ventricular (LV) fibrosis by late gadolinium enhancement (LGE) remains elusive. METHODS: MyoFit46 prospectively recruited ≈500 participants from the 1946 National Survey of Health and Development birth cohort for a cardiovascular magnetic resonance scan at 77 years, assessing LV LGE mass (in grams), calculated using the 3-SD (LGE 3SD ) or 5-SD (LGE 5SD ) methods. Cross-sectional systolic (SBPs) and diastolic BPs (DBPs) were recorded at 36, 43, 53, 63, 69, and 77 years. For each participant and age interval, annual rates of BP change (steepness) were calculated using the observed BPs, and areas under the BP trajectory curve (cumulative burden) were derived using mixed-effects models. Associations between life-course BPs and LV LGE were tested using generalized linear models, adjusted for antihypertensives, demographics, lifestyle, and comorbidities. Time-to-event associations between LV LGE and incident major adverse cardiovascular events (MACE = hospitalizations for coronary artery disease, stroke, heart failure, and atrial/ventricular arrhythmias; N=29 events) were also evaluated. RESULTS: Among 472 participants (54% were men), each 10 mm Hg increment in cross-sectional SBPs at 36 to 69 years was associated with 6% to 11% greater LV LGE 3SD (all P ≤0.033), whereas each sustained 10 mm Hg greater SBP over any age interval from 36 to 69 was associated with 16% to 24% greater LV LGE 3SD at 77 years (all P ≤0.005), with all associations independent of SBP at 77 years. Each 1 mm Hg/y steeper SBP rise during age intervals 36 to 43, 43 to 53, and 53 to 63 years was associated with 6% to 12% greater LV LGE 3SD at 77 years. Results were similar if LV LGE 5SD was used instead. Fewer associations were significant for DBPs. The qualitative presence of LV LGE was associated with greater incident MACE rates (hazard ratio, 2.5 [95% CI, 1.2–5.2]). CONCLUSIONS: Higher life-course cross-sectional BPs, greater cumulative burden, and steeper BP increases were associated with greater LV LGE burden in older age, which was linked to incident MACE. BP trajectories, beyond single-point BP measurements, warrant further investigation as tools to guide BP management strategies.
Renal Cortical Siderosis: Imaging Findings and Clinical Relevance
Shah, Amar S , Chen, Kyle J , Sugi, Mark D

Mayo Clinic

BJR|Case Reports | October 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/bjrcr/uaag043 | PMID 42927408 Get It

Abstract Renal cortical hemosiderosis is the accumulation of iron in the renal cortex. On MRI, this can be inferred by marked cortical T2 hypointensity and loss of signal on in-phase imaging relative to opposed-phase imaging. Although classically associated with paroxysmal nocturnal hemoglobinuria, renal hemosiderosis can be seen in a variety of pathologic conditions associated with acute or chronic renal injury. We present a case of a 59-year-old female that developed acute kidney injury while hospitalized for management of hydronephrosis and hepatic abscess with imaging features on MR angiography and renal parenchymal biopsy consistent with renal cortical hemosiderosis. Combined with other laboratory results, this finding expedited the diagnosis of atypical hemolytic uremic syndrome, a condition with poor prognosis for which timely treatment is essential. Thus, recognition of renal cortical hemosiderosis on imaging may facilitate appropriate clinical workup and timely management.
Impact of Procedural Experience Implanting a Next Generation Left Atrial Appendage Occluder –VERITAS Study Insights
Nair, Devi G , Lakkireddy, Dhanunjaya, Alkhouli, Mohamad, Freixa, X, Ellis, Christopher R. , Makkar, Akash , Shah, Dipak, Weiler, Courtney , Nielsen‐Kudsk, Jens Erik

Mayo Clinic

Europace | October 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/europace/euag289 | PMID 42839306 Get It

African Genetic Similarity Is Associated with Reduced Inflammation and Enhanced Adaptive Immunity in Multiple Myeloma
Pilcher, William , Tang, Hongwei, Ferguson, Katherine, Foltz, Steven , Michaud, Marina E. , Satpathy, Sarthak , Shah, Nishi , Jin, Yuxin , Ohlstrom, Denis, Bakhtiari, Mojtaba , Acharya, Chaitanya R. , Gout, Alexander M. , Keats, Jonathan J. , Dhodapkar, Madhav V. , Avigan, David , Vij, Ravi, Kumar, Shaji , Cho, Hearn Jay , Vlachos, Ioannis S. , Ding, Li , Gnjatic, Sacha , Cole, Craig E. , Nooka, Ajay K. , Lonial, Sagar, Carpten, John, Baughn, Linda B. , Bhasin, Manoj

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033999 | PMID 42832384 Get It

The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
Measuring Symptom Severity and Health-Related Quality-of-Life with Hemorrhoid Treatments: Systematic Review
Soto, Marquise, Srinivasan, Vamshek, Perry, William, Shah, Eric D.

Mayo Clinic

Diseases of the Colon & Rectum | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dcr.0000000000004429 | PMID 42775535 Get It

BACKGROUND: Hemorrhoids are common and relief anchors on symptom improvement. Despite several available treatment options, the optimal patient-reported outcome measure for contemporary clinical trials is not established. OBJECTIVE: We aimed to systematically assess patient-reported outcome measures that measure hemorrhoid symptom severity and/or health-related quality of life. DATA SOURCES: A systematic review was performed using PubMed and Embase (1980-2025). STUDY SELECTION: Prospective development/validation studies evaluating patient-reported outcome measures relevant to hemorrhoidal disease. MAIN OUTCOME MEASURES: Patient-reported outcome measures were evaluated on key measurement properties of reliability, internal consistency, construct validity, and responsiveness according to COSMIN v2.0 criteria. RESULTS: Of the 1,266 total studies reviewed, nine patient-reported outcome measures were identified: seven measure symptom severity and six measure health-related quality-of-life. Three demonstrated reliability, internal consistency, construct validity, and responsiveness. The Patient Reported Outcome Measure-Haemorrhoidal Impact And Satisfaction Score comprehensively measures symptom severity, health-related quality-of-life, and treatment satisfaction. The Hemorrhoidal Disease Symptom Score classifies patients with high or low symptom load, and when used in combination with Short Health Scale-Hemorrhoidal Disease, also measures impact on health-related quality of life. LIMITATIONS: Preference toward specific measures may differ between clinical trials and clinical practice. CONCLUSIONS: We identify two viable patient-reported outcome measures for use in future clinical trials that evaluate hemorrhoid interventions.
BET Bromodomain Pan-D1-Biased Inhibitors with Improved Drug-Like Properties and hERG Profiles as Therapies for Inflammatory Liver Injury
Vail, Nora R. , Doskey, Luke C. , Peterson, Elliott , Scholtz, Cole R. , Gallardo‐Macias, Ricardo , Khanal, Shalil , Buhrow, Sarah A. , McPherson, Joseph E., Sepulveda, Tomás I., Zanon, Trina L., Jerez, Sofia, Alexander, Juliana R. , Gurvich, Vadim J. , Reid, Joel M. , Shi, Ke , Aihara, Hideki , Topczewski, Joseph J., Malhi, Harmeet , Shah, Vijay H. , Pomerantz, William C. K. , Tretyakova, Natalia Y. , Shi, Ke, Topczewski, Joseph J.

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.26434/chemrxiv.15009359/v1 Get It

BET bromodomain inhibitors are efficacious as anti-inflammatory compounds, but clinical translation is hampered by dose-limiting toxicities from non-selective inhibition. We herein report compounds 16 and 26, based on previously reported 4-methyl-1,2,3-triazole-based inhibitor, DW34. 16 has a BRD4 BD1 Ki of 10 nM, and up to 13–38-fold selectivity for BRD4 BD1 over other BD2 domains, and an improved hERG affinity of 4.24 µM over DW34. 26, A biscyclopropyl analog of 16 showed further enhancement of BD1 selectivity over BD2 (26–203-fold), but exhibited more potent hERG inhibition. Compound 16 had improved liver and plasma clearance over DW34, with good biodistribution to the liver, and had an intracellular target-engagement affinity Ki of 92 nM, with reduction of Ccl2, Cxcl1, AST, and ALT in in vitro and in vivo mouse models of liver inflammation. 16 represents a useful lead for treating inflammatory liver diseases, with improved specificity, drug-like properties, and reduced hERG affinity.